Commentary

Video

Lorlatinib in ROS1+ Advanced NSCLC After Crizotinib and Chemotherapy

Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.

Video Player is loading.
Current Time 0:00
Duration 3:13
Loaded: 0%
Stream Type LIVE
Remaining Time 3:13
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected
Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.